AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

SIBN · NASDAQ · Medical - Devices

SI-BONE (SIBN)

Builds iFuse implants for sacroiliac fusion, adult deformity, and pelvic trauma.

$18.74

vs last close+0.29 (+1.57%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	34	39	38	40	40	49	47	49	49	56	53	56
Cost of revenue	7	10	8	8	8	10	10	10	10	12	11	11
Gross profit	27	29	30	32	32	39	38	39	39	45	42	45
	38	41	42	42	40	44	45	46	44	47	47	49
Research & development	4	4	4	4	4	4	5	4	4	4	4	5
	34	37	38	37	36	40	41	42	40	43	43	44
Selling & marketing	27	29	29	29	27	31	31	31	30	33	33	34
General & administrative	8	8	8	8	8	9	10	11	10	10	10	10
Operating income	−11	−13	−12	−10	−8	−5	−7	−7	−5	−2	−5	−5
	1	2	1	1	1	1	1	1	1	1	1	1
Interest income	2	2	2	2	2	2	2	2	2	1	1	1
Interest expense	1	1	1	1	1	1	1	1	1	1	1	1
Other non-operating income	−2	−2	−2	−2	−2	−2	−2	−2	−1	−1	−1	0
Income before tax	−10	−11	−11	−9	−7	−4	−7	−6	−5	−2	−4	−4
Net income from continuing operations	−10	−11	−11	−9	−7	−4	−7	−6	−5	−2	−4	−4
Net income	−10	−11	−11	−9	−7	−4	−7	−6	−5	−2	−4	−4
EPS, basic	−$0.25	−$0.27	−$0.27	−$0.22	−$0.16	−$0.11	−$0.15	−$0.14	−$0.11	−$0.04	−$0.10	−$0.09
EPS, diluted	−$0.25	−$0.27	−$0.27	−$0.22	−$0.16	−$0.11	−$0.15	−$0.14	−$0.11	−$0.04	−$0.10	−$0.09
Weighted average shares, basic	40	41	41	41	42	42	42	43	43	44	44	44
Weighted average shares, diluted	40	41	41	41	42	42	42	43	43	44	44	44
EBITDA	−8	−9	−9	−7	−5	−2	−5	−4	−2	3	−2	−3
Depreciation & amortization	2	2	1	1	1	1	1	1	1	4	2	2
EBIT	−9	−10	−10	−8	−6	−4	−6	−5	−4	−1	−4	−5